Recardio at LSX World Congress USA
- haraldkattnig5
- Sep 14
- 1 min read
San Francisco, September 15, 2025 - Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular diseases, announced today that it is participating in the LSX World Congress USA in Boston.
The congress gathers leaders from the US Biotech, Medtech, and Pharmatech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology.
The event is taking place on September 16-17, 2025 in Boston.
Recardio will be participating and presenting its technology and clinical therapy program for cardiovascular diseases.
About Recardio
Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.
Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction. This trial is planned to initiate in 2026 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.
For more information, visit: www.recardio.eu or contact pr@recardio.eu